Article and Video CATEGORIES

Cancer Journey

Search By

The Potential Value of Repeat Biopsies in Acquired Resistance
Author
GRACE Videos and Articles
GRACE Cancer Video Library - Lung

GCVL_LU_Potential_Value_Repeat_Biopsies_Acquired_Resistance

 

MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

So, after initial therapy with EGFR tyrosine-kinase inhibitors, patients often develop — always, really, develop progressive disease, known as resistance, where the tumor has become resistant to therapy. How we manage patients and how we treat their disease, after development of resistance, is a complicated area. One way we can learn a little bit more about a patient’s tumor, and help to refine our decision making, is to do a biopsy of a site of progressive disease.

What we learn from a biopsy really is two-fold. The first, and easiest part, is the pathologist looks at it under the microscope and says, “is this still non-small cell lung cancer, or is this changed?” A relatively rare phenomenon is transformation of non-small cell lung cancer into small cell lung cancer — it happens maybe one to three percent of the time, but it’s a relevant thing to find, and we would adjust chemotherapy as a consequence of this.

Another thing to look for when we biopsy a site of resistance is acquisition of new mutations. One of the most common new mutations identified, it happens in about two-thirds of patients, is a secondary mutation called T790M. The important thing about identifying T790M is that we can now, in clinical trials, and hopefully in the future, with FDA approved drugs, target that T790M mutation with a new drug; we have two new drugs that are being developed now, one is called rociletinib and one is called mereletinib — these are specifically designed to target T790M. Now, importantly, any given biopsy has a chance of finding a mutation that’s present, and it also has a chance of missing it — whether that’s because we biopsied a site that didn’t have that mutation or, for whatever reason, our testing didn’t identify the T790M mutation. I think it’s important to know that as a caveat before going in to re-biopsy, but I do think that biopsying tumors at the time of resistance to EGFR tyrosine-kinase inhibitors does help devise the next best therapy for a patient.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancer OncTalk
Article
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:
Article
View the full Targeted Therapies in Lung Cancer Patient forum from 2023 in YouTube and embedded here! 

Forum Discussions

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Hi Oaktowngrrl,  Welcome to Grace.  I'm so sorry you're going through this.

 

 Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...

Recent Comments

JOIN THE CONVERSATION
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on
Hi Blaze,

 

As much as I…
By JanineT GRACE … on